Cangrelor

• Description :

  Cangrelor (AR-C69931MX), an adenosine triphosphate analogue, is an intravenous, reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor directly blocks adenosine diphosphate (ADP) -induced activation and aggregation of platelets. Cangrelor is also a nonspecific GPR17 antagonist[1][2].

• Product Name Alternative :

  AR-C69931MX

• UNSPSC :

  12352005

• Hazard Statement :

  H315-H319-H320

• Target :

  P2Y Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology; Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/cangrelor.html

• Solubility :

  10 mM in DMSO

• Smiles :

  CSCCNC1=C2C(N([C@H]3[C@H](O)[C@H](O)[C@@H](COP(OP(C(Cl)(Cl)P(O)(O)=O)(O)=O)(O)=O)O3)C=N2)=NC(SCCC(F)(F)F)=N1

• Molecular Formula :

  C17H25Cl2F3N5O12P3S2

• Molecular Weight :

  776.36

• Precautions :

  P264-P280-P302+P352-P305+P351+P338-P362

• References & Citations :

  [1]Bhattad VB, , et al. Intravenous cangrelor as a peri-procedural bridge with applied uses in ischemic events. Ann Transl Med. 2019;7 (17) :408.|[2]Zhan T, Wei T, et al. Cangrelor alleviates bleomycin-induced pulmonary fibrosis by inhibiting platelet activation in mice. Mol Immunol. 2020;120:83-92.|[3]Bekő K, et al. Contribution of platelet P2Y12 receptors to chronic Complete Freund's adjuvant-induced inflammatory pain. J Thromb Haemost. 2017;15 (6) :1223-1235.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  P2Y12 Receptor

• CAS Number :

  [163706-06-7]